Trinity Biotech (TRIB) has released an update.
Trinity Biotech plc is advancing its presence in the diabetes management sector by initiating a market study in India for its next generation Continuous Glucose Monitoring (CGM) technology, aimed at addressing the country’s growing diabetes challenge. The company’s non-binding collaboration with Bayer aims to enhance CGM access and affordability in India, where over 100 million people live with diabetes. Trinity Biotech’s development emphasizes user-friendly design, cost reduction, and the potential to transform diabetes care in emerging markets.
For further insights into TRIB stock, check out TipRanks’ Stock Analysis page.
